10月20日 - ** 药物开发商Alto NeuroscienceANRO.N股价盘前上涨8.2%至6.58美元
** 公司表示计划加速开发针对耐药性抑郁症患者的实验性药物ALTO-207
** 耐药性抑郁症是一种重度抑郁症，患者在尝试了至少两种不同的抗抑郁药物并服用足够剂量和足够时间后，症状仍未得到改善。
** 今天早些时候宣布的 5000 万美元私募资金用于支持 ALTO-207 - ANRO 的扩大开发
** 公司预计在 2027 年初开始后期研究
** 截至上一交易日收盘，股价累计上涨 43.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.